Does Scleroderma Affect the Urinary Bladder?
Yes, systemic sclerosis (scleroderma) does affect the urinary bladder, causing lower urinary tract symptoms (LUTS) in approximately 19-28% of patients, though this manifestation is often overlooked and not addressed in major treatment guidelines.
Prevalence and Clinical Significance
The urinary bladder is indeed affected in scleroderma, with moderate to severe LUTS occurring in about one-fifth of SSc patients 1. A Japanese study found an even higher prevalence of overactive bladder (OAB) at 27.9% 2. Importantly, these symptoms are out of proportion to what would be expected based on age, sex, and usual risk factors alone, indicating SSc-specific mechanisms 3.
Key Clinical Features
The most common urinary manifestations include:
- Storage symptoms (most frequent at 63%) - urgency, frequency, nocturia
- Voiding symptoms (19.3%) - hesitancy, weak stream
- Post-voiding symptoms (12.6%) - incomplete emptying
- Urinary incontinence and overactive bladder - significantly more prevalent than in healthy matched controls 4
Risk Factors for Bladder Involvement
Patients at highest risk for moderate to severe LUTS include those with:
- Modified Rodnan skin score ≥20 points (adjusted OR 7.64) 1
- Gastrointestinal symptoms (adjusted OR 5.78) 1
- Longer disease duration (mean 15.4 vs 11.2 years) 2
- Anti-centromere antibody positivity 2
- Gastroesophageal reflux disease 2
- Sarcopenia and reduced bone mineral density 4
Pathophysiology
The mechanisms underlying bladder involvement are multifactorial and include:
- Fibrosis of bladder tissue (though symptoms don't always correlate with histological severity) 5
- Autonomic dysfunction/dysautonomia - detected in over half of affected patients 5
- Possible antibody-mediated mechanisms (emerging evidence) 3
- Functional restriction from systemic disease
Impact on Quality of Life
The severity of LUTS directly correlates with poorer quality of life (moderate positive correlation, rho = 0.560) 1. Despite this significant impact, urinary symptoms are frequently neglected during routine SSc assessments 1.
Critical Clinical Caveat
Major treatment guidelines for systemic sclerosis (including the 2025 EULAR recommendations and 2023 state-of-the-art reviews) do not address urinary bladder involvement 6, 7. The guidelines focus on Raynaud's phenomenon, digital ulcers, pulmonary arterial hypertension, scleroderma renal crisis, skin fibrosis, interstitial lung disease, gastrointestinal manifestations, and musculoskeletal symptoms—but bladder symptoms are conspicuously absent from screening and treatment algorithms.
Clinical Approach
Given the lack of guideline-based recommendations, clinicians should:
- Actively screen for LUTS in SSc patients, particularly those with extensive skin involvement and GI symptoms
- Consider using validated questionnaires like the International Prostate Symptom Score (IPSS) or OAB Symptom Score (OABSS)
- Refer to urology when moderate to severe symptoms are identified
- Recognize that urodynamic alterations may be present even without severe symptoms 5
The absence of bladder involvement from major SSc guidelines represents a significant gap in comprehensive disease management, despite clear evidence of its prevalence and impact on patient quality of life.